| Size | Price | Stock | Qty |
|---|---|---|---|
| 100U |
|
||
| 500U |
|
||
| 1KU |
|
||
| Other Sizes |
| Targets |
The primary targets of lactate oxidase are L-lactate and molecular oxygen. The enzyme specifically catalyzes the oxidation of L-lactate, showing high substrate specificity. Lactate oxidase can destroy lactate-activated RAS and PI3K oncogenic signaling, making it potentially useful in cancer diagnosis and treatment. The enzyme belongs to a group of FMN-dependent enzymes that catalyze the conversion of lactate to pyruvate with the release of hydrogen peroxide.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that lactate oxidase effectively catalyzes the oxidation of L-lactate to pyruvate, with oxygen as the primary electron acceptor. The enzyme is used in enzymatic detection systems for monitoring metabolic and fermentation processes. Its substrate specificity, stability, and utility make it valuable for clinical diagnostics and food analysis. The enzyme can also destroy lactate-activated RAS and PI3K oncogenic signaling.
|
| ln Vivo |
In vivo activity data for lactate oxidase are related to its potential use in cancer therapy. By depleting lactate, the enzyme can disrupt lactate-activated RAS and PI3K oncogenic signaling, which may inhibit tumor growth. The enzyme has been studied for its potential in cancer diagnosis and treatment. However, specific in vivo pharmacological studies are limited.
|
| Enzyme Assay |
Non-cellular assays for lactate oxidase typically involve measuring enzyme activity using L-lactate as substrate. The reaction produces pyruvate and H₂O₂, which can be detected colorimetrically or fluorometrically using coupled enzyme assays or by measuring oxygen consumption. One unit of enzyme activity is typically defined as the amount of enzyme that oxidizes 1 µmol of L-lactate per minute under specified conditions.
|
| Cell Assay |
In vitro cellular assays for lactate oxidase are conducted using cancer cell lines to assess its effects on lactate metabolism and oncogenic signaling. Cells are treated with the enzyme, and lactate levels in the culture medium are measured. The effects on RAS and PI3K signaling are assessed by Western blotting. Cell proliferation and viability are measured to evaluate the enzyme's potential anticancer activity.
|
| Animal Protocol |
In vivo animal experiments for lactate oxidase are limited. The enzyme may be studied in tumor xenograft models to assess its effects on tumor growth and lactate metabolism. The enzyme is administered locally or systemically, and tumor size, lactate levels, and signaling pathway activation are assessed. These studies evaluate the enzyme's potential as a cancer therapeutic.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of lactate oxidase are not well-characterized, as the enzyme is primarily used as a research reagent and diagnostic tool. The enzyme is a protein with a molecular weight of approximately 80-130 kDa (depending on source). It is typically supplied as a yellowish amorphous powder or lyophilized preparation. The enzyme is stable under appropriate storage conditions and should be kept at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicological data for lactate oxidase are limited, as it is an enzyme used in diagnostic and research applications. The enzyme is not intended for human therapeutic use. Standard laboratory safety precautions should be followed when handling the enzyme. No significant toxicity has been reported for the enzyme in research settings.
|
| References | |
| Additional Infomation |
Other information includes lactate oxidase's role as a flavin-dependent oxidase that catalyzes the oxidation of L-lactate to pyruvate with the concurrent production of hydrogen peroxide. It is commonly used in lactate assays, biosensors, and food industry applications for lactate analysis. The enzyme is also known as lactate oxidative decarboxylase, lactic oxygenase, and L-lactate monooxygenase. It can be used in cancer research to destroy lactate-activated RAS and PI3K oncogenic signaling.
|
| Molecular Formula |
C2H6
|
|---|---|
| Molecular Weight |
30.06900
|
| Exact Mass |
30.047
|
| CAS # |
9028-72-2
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
1.026
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 33.2557 mL | 166.2787 mL | 332.5574 mL | |
| 5 mM | 6.6511 mL | 33.2557 mL | 66.5115 mL | |
| 10 mM | 3.3256 mL | 16.6279 mL | 33.2557 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
